Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers

Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension and congestive heart failure. Preclinical data show that ACE plays a role on both innate and adaptive immune responses. Since interactions between ACE inhibitors and immune checkpoint inhibitors (ICIs) have not...

Descripción completa

Detalles Bibliográficos
Autores principales: Medjebar, Soleine, Truntzer, Caroline, Perrichet, Anaïs, Limagne, Emeric, Fumet, Jean-David, Richard, Corentin, Elkrief, Arielle, Routy, Bertrand, Rébé, Cédric, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595630/
https://www.ncbi.nlm.nih.gov/pubmed/33178495
http://dx.doi.org/10.1080/2162402X.2020.1836766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595630/
https://www.ncbi.nlm.nih.gov/pubmed/33178495
http://dx.doi.org/10.1080/2162402X.2020.1836766

Ejemplares similares